MA55909A - Inhibiteurs de cdk - Google Patents

Inhibiteurs de cdk

Info

Publication number
MA55909A
MA55909A MA055909A MA55909A MA55909A MA 55909 A MA55909 A MA 55909A MA 055909 A MA055909 A MA 055909A MA 55909 A MA55909 A MA 55909A MA 55909 A MA55909 A MA 55909A
Authority
MA
Morocco
Prior art keywords
cdk inhibitors
cdk
inhibitors
Prior art date
Application number
MA055909A
Other languages
English (en)
Inventor
Hu He
Zhilong Hu
Fei Zhang
Wenge Zhong
Xiaotian Zhu
Original Assignee
Qilu Regor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Regor Therapeutics Inc filed Critical Qilu Regor Therapeutics Inc
Publication of MA55909A publication Critical patent/MA55909A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
MA055909A 2019-05-05 2020-05-05 Inhibiteurs de cdk MA55909A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019085494 2019-05-05

Publications (1)

Publication Number Publication Date
MA55909A true MA55909A (fr) 2022-03-16

Family

ID=73051265

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055909A MA55909A (fr) 2019-05-05 2020-05-05 Inhibiteurs de cdk

Country Status (18)

Country Link
US (9) US20220296595A1 (fr)
EP (2) EP3966213A4 (fr)
JP (4) JP7671425B2 (fr)
KR (2) KR20260004524A (fr)
CN (4) CN114364675A (fr)
AU (4) AU2020269469B2 (fr)
BR (1) BR112021022105A2 (fr)
CA (1) CA3138973A1 (fr)
CL (1) CL2021002903A1 (fr)
CO (1) CO2021016504A2 (fr)
EA (1) EA202193015A1 (fr)
IL (2) IL315588A (fr)
MA (1) MA55909A (fr)
MX (4) MX2021013531A (fr)
PH (1) PH12021552805A1 (fr)
SG (1) SG11202112229UA (fr)
TW (4) TWI875756B (fr)
WO (2) WO2020224568A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3728228A1 (fr) 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la phosphatidylinositol phosphate kinase
SG11202108004VA (en) * 2019-01-29 2021-08-30 Beta Pharma Inc 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
BR112021022105A2 (pt) * 2019-05-05 2021-12-28 Qilu Regor Therapeutics Inc Inibidores de cdk
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN114516856B (zh) * 2020-11-20 2025-05-23 安徽中科拓苒药物科学研究有限公司 二氢异喹啉酮和异吲哚啉酮衍生物及其用途
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023143482A1 (fr) * 2022-01-29 2023-08-03 上海辉启生物医药科技有限公司 Composé ou sel de 2-aminopyrimidine, son procédé de préparation et son utilisation
AU2023248394A1 (en) * 2022-04-08 2024-10-31 Baerenkraft Therapeutics, Llc Cdk9 inhibitors
KR20250054814A (ko) * 2022-09-05 2025-04-23 티와이케이 메디슨즈, 인코포레이티드 Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 용도
WO2024107746A1 (fr) * 2022-11-15 2024-05-23 Larkspur Biosciences Inhibiteurs et agents de dégradation de protéine pip4k
KR20260043126A (ko) 2023-07-27 2026-03-31 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 산소 함유 축합 트리시클릭 유도체 및 이의 제조 방법과 용도
WO2025102352A1 (fr) 2023-11-17 2025-05-22 Genentech, Inc Formes salines et solides d'un inhibiteur de cdk
WO2025111845A1 (fr) 2023-11-29 2025-06-05 Genentech, Inc. Formes salines et solides d'un inhibiteur de cdk
WO2025185643A1 (fr) * 2024-03-05 2025-09-12 浙江同源康医药股份有限公司 Composé utilisé en tant qu'inhibiteur de la protéine kinase cdk4 et utilisation d'un composé
CN119751339A (zh) * 2024-12-30 2025-04-04 中国科学院长春应用化学研究所 一种六元环状鸟氨酸衍生单体、改性尼龙6及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
DE60201074T2 (de) 2001-03-08 2005-09-15 Smithkline Beecham Corp. Pyrazolopyridinderivate
WO2002102783A1 (fr) 2001-06-19 2002-12-27 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
WO2003015776A1 (fr) 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Derives de thiazolyl 2,4,5-trisubstitue et activite anti-inflammatoire associee
DK1438053T3 (da) 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
AU2002357740A1 (en) 2001-12-11 2003-06-23 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
EP1469810A4 (fr) 2002-01-04 2009-01-14 Univ Rockefeller Compositions et procedes de prevention et de traitement de troubles lies au peptide beta-amyloide
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
DE602005024382D1 (de) 2004-04-13 2010-12-09 Astellas Pharma Inc Polycyclische pyrimidine als kaliumionenkanal-modulatoren
EP1799652A1 (fr) 2004-10-13 2007-06-27 Wyeth Analogues d'anilino-pyrimidine a substitution n-benzenesulfonyle
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
WO2007149427A2 (fr) 2006-06-22 2007-12-27 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
US8258129B2 (en) * 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
MX2010006457A (es) 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
EA019094B1 (ru) 2008-08-22 2014-01-30 Новартис Аг Пирролопиримидины и их применение
UY32203A (es) 2008-10-29 2010-05-31 Astrazeneca Ab Amino pirimidinas y su uso en terapia
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
NZ598262A (en) 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
KR101830455B1 (ko) 2010-04-13 2018-02-20 노파르티스 아게 시클린 의존성 키나제 ４ 또는 시클린 의존성 키나제 （ｃｄｋ４／６） 억제제 및 ｍｔｏｒ 억제제를 포함하는 암 치료를 위한 조합물
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
MY161925A (en) 2011-07-27 2017-05-15 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
WO2013173506A2 (fr) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Procédé de traitement d'une dégradation musculaire
JP6435315B2 (ja) 2013-03-15 2018-12-05 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高活性抗新生物薬及び抗増殖剤
WO2014181287A1 (fr) 2013-05-09 2014-11-13 Piramal Enterprises Limited Composés hétérocyclyliques et leurs utilisations
KR102232595B1 (ko) 2013-08-30 2021-03-26 피티씨 테라퓨틱스, 인크. 치환된 피리미딘 bmi-1 저해제
EP3057954A2 (fr) 2013-10-18 2016-08-24 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
CN104761544B (zh) 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
FR3018704B1 (fr) 2014-03-20 2016-03-18 Rexam Healthcare La Verpillier Dispositif de distribution de liquide comprenant un capuchon de protection.
RU2016141934A (ru) 2014-04-04 2018-05-07 Сирос Фармасьютикалз, Инк. Ингибиторы циклин-зависимой киназы 7 (cdk7)
US20150297608A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents
WO2016014904A1 (fr) * 2014-07-24 2016-01-28 Beta Pharma, Inc. Dérivés de 2-h-indazole en tant qu'inhibiteurs de la kinase dépendante de la cycline (cdk) et leurs utilisations thérapeutiques
US10241219B2 (en) 2014-07-25 2019-03-26 Westerngeco L.L.C. Sensor device having elongated housing
WO2016015604A1 (fr) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Composés en tant que petites molécules inhibitrices de la cdk et leurs utilisations
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
HK1245791A1 (zh) 2015-01-20 2018-08-31 阿尔维纳斯运营股份有限公司 用於雄激素受体的靶向降解的化合物和方法
ES2806206T3 (es) 2015-03-11 2021-02-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivado de 2-hidrógeno pirazol sustituido que sirve como fármaco anticanceroso
JP6598862B2 (ja) 2015-07-28 2019-10-30 三菱電機株式会社 運転支援装置
TWI736578B (zh) * 2016-02-06 2021-08-21 大陸商上海複尚慧創醫藥研究有限公司 6-5元稠合唑環衍生物及其藥物組合物，以及作為藥物的應用
CN107286134B (zh) * 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用
IL307931A (en) * 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
CN110818690B (zh) 2016-07-26 2021-08-10 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN112225724B (zh) 2016-09-07 2022-04-29 江苏豪森药业集团有限公司 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
TWI732083B (zh) * 2016-12-22 2021-07-01 大陸商貝達藥業股份有限公司 苯并咪唑衍生物、其藥物組合物及其應用
WO2018121766A1 (fr) * 2016-12-30 2018-07-05 上海医药集团股份有限公司 Composé hétérocyclique fusionné contenant de l'azote, procédé de préparation, intermédiaire, composition et utilisation associés
CN108794452B (zh) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
WO2019023553A1 (fr) 2017-07-28 2019-01-31 Arvinas, Inc. Composés et procédés pour la dégradation ciblée du récepteur des androgènes
JP7233743B2 (ja) 2017-08-11 2023-03-07 晟科薬業（江蘇）有限公司 プロテインキナーゼ阻害剤としての１ｈ－ピラゾロ［４，３－ｈ］キナゾリン系化合物
CN109503573A (zh) * 2017-09-14 2019-03-22 昆明圣加南生物科技有限公司 2-取代苯胺基嘧啶衍生物及其用途
US10519136B2 (en) * 2017-12-29 2019-12-31 Accutar Biotechnology Dual inhibitors of PARP1 and CDK
CA3088381A1 (fr) * 2018-01-29 2019-08-01 Beta Pharma, Inc. Derives de 2-h-indazole en tant qu'inhibiteurs de cdk4 et cdk6 et leurs utilisations therapeutiques
CN110156754B (zh) 2018-02-10 2023-10-03 杭州百诚医药科技股份有限公司 一种三取代嘧啶衍生物对蛋白激酶的抑制作用
CN108484606B (zh) 2018-03-16 2020-03-06 江南大学 一种嘧啶并[4,5-f]喹唑啉类化合物及其应用
CN113166110B (zh) 2018-12-12 2023-08-11 暨南大学 2-氨基嘧啶类化合物及其应用
JP2022517723A (ja) 2018-12-19 2022-03-10 キーセラ・（スーチョウ）・ファーマシューティカルズ・カンパニー・リミテッド Ｃｄｋ阻害剤としての大環状化合物、その製造方法及びその医薬品における応用
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
BR112021022105A2 (pt) 2019-05-05 2021-12-28 Qilu Regor Therapeutics Inc Inibidores de cdk
KR20250119652A (ko) * 2019-06-14 2025-08-07 가꼬우 호징 관세이 가쿠잉 다환방향족 화합물
TW202115042A (zh) 2019-06-21 2021-04-16 大陸商江蘇豪森藥業集團有限公司 芳基磷氧化物類衍生物抑制劑、其製備方法和應用
CA3146375A1 (fr) 2019-07-10 2021-01-14 Aucentra Therapeutics Pty Ltd Derives de 4-(imidazo [l, 2-a] pyridine-3-yl)-n-(pyridinyl) pyrimidine-2-amine en tant qu'agents therapeutiques
US20230118053A1 (en) 2020-03-27 2023-04-20 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Combination of anti-her2 antibody and cdk inhibitior for tumor treatment

Also Published As

Publication number Publication date
BR112021022105A2 (pt) 2021-12-28
PH12021552805A1 (en) 2022-12-05
CN118406049A (zh) 2024-07-30
MX2025008593A (es) 2025-08-01
US20250275972A1 (en) 2025-09-04
KR20260004524A (ko) 2026-01-08
AU2020269469A1 (en) 2021-12-09
WO2021226140A1 (fr) 2021-11-11
CN114364675A (zh) 2022-04-15
US12285429B2 (en) 2025-04-29
US20220296595A1 (en) 2022-09-22
US20250325544A1 (en) 2025-10-23
AU2026201001A1 (en) 2026-03-05
EP4146647A1 (fr) 2023-03-15
TW202144351A (zh) 2021-12-01
WO2020224568A1 (fr) 2020-11-12
TW202521536A (zh) 2025-06-01
JP2022531687A (ja) 2022-07-08
US20250064806A1 (en) 2025-02-27
IL287767B2 (en) 2025-02-01
AU2026200999A1 (en) 2026-03-05
MX2025008591A (es) 2025-08-01
EA202193015A1 (ru) 2022-03-17
KR20220004755A (ko) 2022-01-11
CN115803327A (zh) 2023-03-14
TW202108572A (zh) 2021-03-01
JP7671425B2 (ja) 2025-05-02
IL315588A (en) 2024-11-01
JP7689984B2 (ja) 2025-06-09
KR102898876B1 (ko) 2025-12-12
MX2025008589A (es) 2025-08-01
CL2021002903A1 (es) 2022-07-08
TWI875756B (zh) 2025-03-11
CA3138973A1 (fr) 2020-11-12
CN115803327B (zh) 2024-02-13
JP2025128182A (ja) 2025-09-02
US20250275971A1 (en) 2025-09-04
AU2021268648A1 (en) 2023-01-19
CO2021016504A2 (es) 2022-01-17
MX2021013531A (es) 2022-02-11
IL287767B1 (en) 2024-10-01
EP3966213A1 (fr) 2022-03-16
IL287767A (en) 2022-01-01
US20240066031A1 (en) 2024-02-29
CN120040446A (zh) 2025-05-27
US20240033264A1 (en) 2024-02-01
TW202545942A (zh) 2025-12-01
US20250281487A1 (en) 2025-09-11
JP2025090693A (ja) 2025-06-17
JP2023525005A (ja) 2023-06-14
US20230174512A1 (en) 2023-06-08
EP3966213A4 (fr) 2023-04-19
SG11202112229UA (en) 2021-12-30
TWI895410B (zh) 2025-09-01
EP4146647B1 (fr) 2026-04-15
AU2020269469B2 (en) 2026-01-29

Similar Documents

Publication Publication Date Title
EP3966213A4 (fr) Inhibiteurs de cdk
EP4007752C0 (fr) Inhibiteurs de kif18a
EP4007753C0 (fr) Inhibiteurs de kif18a
IL283639A (en) Kif18a inhibitors
MA54550A (fr) Inhibiteurs de kif18a
EP4007756C0 (fr) Inhibiteurs de kif18a
PT3980417T (pt) Inibidores de prmt5
DK3740479T3 (da) Dna-pk-hæmmere
EP3833355A4 (fr) Inhibiteurs de prmt5
EP3801503A4 (fr) Inhibiteurs de sarm1
EP3843714A4 (fr) Inhibiteurs de cd73
MA52813A (fr) Inhibiteurs de sarm1
MA52413A (fr) Inhibiteurs de cd73
EP3980011A4 (fr) Inhibiteurs de sarm1
MA52809A (fr) Inhibiteurs de sarm1
EP3761992A4 (fr) Inhibiteurs d'arginase
EP3856176A4 (fr) Inhibiteurs de vap-1
EP3787635A4 (fr) Inhibiteurs de cd73
EP3817736A4 (fr) Inhibiteurs de pikfyve
EP3999517A4 (fr) Inhibiteurs de cd73
EP3938358A4 (fr) Inhibiteurs de rad51
EP4077282A4 (fr) Inhibiteurs de prmt5
MA55477A (fr) Inhibiteurs de hpk1
EP3856194A4 (fr) Inhibiteurs de vap-1
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors